July 10, 2019
Please take 10 minutes to participate in the ID Physician Compensation Survey to help us better understand and report on trends in the profession and, in turn, serve you better by advocating for fair compensation.
Read More
IDSA has awarded 23 institutions the designation of Antimicrobial Stewardship Centers of Excellence (CoE).
Read More
The Advisory Committee on Immunization Practices (ACIP) voted at its June meeting to remove the pneumococcal conjugate vaccine 13-valent (PCV13) from the adult vaccination schedule.
Read More
In this feature, a panel of IDSA members identifies and critiques important new studies in the current literature that have a significant impact on the practice of infectious diseases medicine.
Reviews in this issue: Improving Vaccination Rates: Can Legislation Have an Impact?, Placing PICCs for Antibiotics: Potential Undue Risks, and Fluoroquinolone Prophylaxis and Meropenem Non-susceptible aeruginosa: A Cautionary Tale.
Members of the HIVMA Board of Directors met with Department of Health and Human Services Secretary Alex Azar, II, HHS Assistant Secretary for Health Brett Giroir, MD, and Director of the Office of HIV/AIDS and Infectious Diseases Policy Tammy Beckham during their recent board meeting to discuss the administration’s End the HIV Epidemic initiative.
Read More
IDSA continues to lead a coalition of stakeholders to urge the Centers for Medicare and Medicaid Services (CMS) and Congress to enact key policies to improve antibiotic reimbursement and strengthen stewardship.
Read More
The Microsporidiosis Section of the HHS Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV has been updated with information on microsporidia that have been documented in human infections, their taxonomy, data on the use of nitazoxanide for the treatment of microsporidiosis and the availability of fumagillin for the treatment of Enterocytozoon bieneusi infection, with contact information for obtaining the medication from Sanofi.
Read More
The U.S. Food & Drug Administration has approved changes to the label for the HIV medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide).
Read More
IDSA Board member Ann Macintyre, DO, FIDSA, authored an op-ed for STAT about the importance of presidential candidates being prepared to discuss their plans for infectious diseases.
Read More
Here’s a glance at the latest discussions happening on MyIDSA, IDSA’s members-only online community (login required).
Read More